Information Library
Go-to-Market
To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.
- Sort by: Most Recent
- Title
-
Early Phase Optimization Strategies
November 18, 2009
As payers balk at rising drug prices and patent expirations threaten the industry’s revenue streams, pharmaceutical companies worldwide are looking for ways to cut costs associated with drug development and, simultaneously, speed the process up. -
Rewarding Innovation and Value: What is the Role of Comparative Effectiveness Research
October 6, 2009
The impact of comparative effectiveness research on the future of drug development. -
Outsourcing for Pan-European launch success
August 13, 2009
This study is about research company PharmaMar and the ambitious pan-European launch of their brand Yondelis®. And how, without any sales infrastructure, they were meeting and beating targets faster than anyone thought possible. -
For Investigors: Market Situation
July 17, 2009
Learn about the clinical trial market situation. -
Incremental Cost of Otitis Media Among Children in the United States
June 25, 2009
Using a nationally representative data source, the study estimates the medical cost of treating otitis media among children in the US. The costs are estimated at $2 billion in 2005. -
Poised for success
June 16, 2009
Learn how a holistic life cycle approach can improve your commercial organization's productivity and flexibility -
QUINTILES APPOINTS RICHARD PILNIK TO HEAD INNOVEX
April 7, 2009 - Quintiles Transnational Corp. announced the appointment of Richard (Rich) Pilnik to serve as president of Innovex. -
A Testimonial About Innovex Portugal
March 30, 2009
A testimonial about commercialization through Innovex. -
Launching a Successful Brand in a Genericized Market
March 27, 2009
The market for this particular category of muscle relaxants was owned by 10 mg tablets, both branded and generic. Our customer wanted to launch a 5 mg tablet that – contrary to physician and pharmacist preconceptions – was fully as effective as the 10 mg version. -
Adrian McKemey, Ph.D.
March 25, 2009
Adrian leads the Product Development and Commercialization consulting practice at Quintiles Global Consulting.